Reuters logo
BRIEF-Sinclair Pharma expects H2 sales to be considerably higher than H1​
September 19, 2017 / 6:28 AM / a month ago

BRIEF-Sinclair Pharma expects H2 sales to be considerably higher than H1​

Sept 19 (Reuters) - SINCLAIR PHARMA PLC:

* ‍HY GROUP REVENUES INCREASED 16% TO £20.1 MILLION​

* ‍HY GROSS MARGIN INCREASED TO 72.4%​

* ‍EXPECT H2 SALES TO BE CONSIDERABLY HIGHER THAN H1​

* EXPECT TREND OF SALES AND PROFITABILITY MOMENTUM TO CONTINUE FOR MEDIUM TERM​

* HY LOSS BEFORE TAXATION ‍7.2 MILLION POUNDS VERSUS LOSS OF 8.6 MILLION POUNDS A YEAR AGO Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below